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The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic ﬁeld. Many types of
cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compounds
were disoveredandamongthemcarboplatinandoxaliplatinare themainCisplatinanaloguesshowingsimilarclinicaleﬃcacywith
a safer toxicity proﬁle. Lipoplatin is a new liposomal cisplatin formulation which seems to have these characteristics. Lipoplatin
was shown to be eﬀective in NSCLC both in phase 2 and phase 3 trials, with the same response rate of Cisplatin, a comparable
overallsurvival but less toxicity. A new protocol aimingto elucidate the double capacity of Lipoplatinto act as a chemotherapeutic
and angiogenetic agent in triple-negative breast cancer patients is upcoming.
1.Introduction
In the present scenario of cancer medical treatment, Plat-
inum compounds and Cisplatin are considered important
drugsby cliniciansand are useful in many typesofneoplastic
diseases.
Their use is especially devoted to the treatment of
epithelial malignancies, but also lymphoma and sarcoma
could be sensitive to these drugs. From its discovery in 1965,
cisplatin had a milestone achievement in clinical oncology,
and has saved thousands of lives of testicular cancer patients.
As a matter of fact, Cisplatin is recommended for the
treatment of metastatic testicular, ovarian, and transitional
bladder cancer and also nonsmall cell lung cancer (NSCLC),
cervical cancer, head and neck cancer, esophageal cancer,
gastric cancer, breast cancer and many other malignancies.
The principallimitations foritsuse are dueto itspossible
severe toxicities, especially nephrotoxicity, neuropathy, oto-
toxicity, and hematological toxicities. The most important
signiﬁcant toxicity is linked to renal damage. For this reason,
many other compounds have been searched in order to
overcome this problem. In the recent years, two other
Cisplatin-like drugs were introduced in clinical practice,
such as carboplatin and oxaliplatin. Carboplatin is mainly
used in the treatment of NSCLC and ovarian cancer while
Oxaliplatin is mainly used in colorectal carcinoma.
Thesetwodrugsareburdenedbydiﬀerenttoxicities,such
as hematological toxicity for Carboplatin and neurotoxicity
for Oxaliplatin.
Moreover, their antitumor eﬃcacy is very diﬀerent
from Cisplatin, whose use cannot be substituted in some
pathologies like testicular cancer and lung cancer, but also
bladder and biliary tumors.
For these reasons, the research of diﬀerent compounds
having platinum eﬃcacy without the limitation ofits general
toxicity are currently underway.
Lipoplatin was recently introduced in clinical practice
after the observation of its eﬃcacy and mild toxicity.
2.The LipoplatinDrug
Liposomesareanimportantadvancedtechnologythatallows
to deliver active molecules to the disease’ site one and
nowadaysseveralformulationare enteredin clinicalpractice.2 Chemotherapy Research and Practice
Liposome tecnologyhas reached the “secondgeneration”
with long circulating liposome built, modulating lipid com-
position size and charge of the vescicles [1].
Lipoplatin TM is a new liposoma cisplatin formulation
developed in order to reduce the systemic toxicity of
cisplatin, enhancing tumor targeting [2].
This molecule measures 110nm and is composed of
a lipid shell made of dipalmitoyl-phosphatidyl glycerol
(DPPG), soy, phosphatidyl-choline (SPC/3), cholesterol
(CHOL), methoxy-polyethylene, and glycol-distearoyl phos-
phatidylethanolamine lipid conjugate (mMPEG 2000-
DSPE), containing a central core of Cisplatinum with a ratio
of Cisplatinum to lipids of 8.9% Cisplatin and 91.1% total
lipids. A PEG polymer coating is added to the molecule.
This modiﬁed formulation is not detected by macropha-
ges and immune cells, and, therefore, it circulates longer in
body ﬂuids and tissues, with accumulation preferentially in
primary tumor sites and metastases.
Preclinical trials have demonstrated the ability of this
molecule to be concentrated up to 50 times more in
malignant tissues than in normal tissues [2].
While Cisplatin eﬄux is regulated by at least two copper
of eﬄux transporter, Lipoplatin is proposed to bypass this
process. Thus Lipoplatin might have application even in
previously Cisplatin-pretreated patients who have developed
resistant tumours.
3.PhaseIStudiesandLipoplatin
Pharmacokinetics
In a Phase I study on 27 patients with pretreated (2nd-
or 3rd- line treatment) stage IV cancer (19 pancreatic
carcinoma, 6 renal cell carcinoma, 1 gastric cancer, and 1
squamous cell carcinoma of the head and neck SCCHN),
Lipoplatin dose was escalated from 25 to 125mg/m2,a n di t
was administered as an 8-hour infusion diluted in 1L 5%
dextrose, repeated every 2 weeks without need for pre or
posthydration. Three patients were also treated at higher-
dose levels, one at 200, 250, and 300mg/m2, respectively [2].
There were no deaths or other serious adverse events (SAEs).
Lipoplatin had mild hematological and gastrointestinal toxi-
city, and it did not show any nephrotoxicity, neurotoxicity or
ototoxicity,nor caused hair loss. Grade 1 and 2 myelotoxicity
(neutropenia) and grade 1 and 2 GI tract toxicity (vomiting)
were observed only at the dose of 125mg/m2. The maximum
tolerated dose (MTD) was not reached even when the dose
was increased up to 350mg/m2 in one patient as a single
infusion. No other toxicity was observed even with repeated
doses. At the beginning of the infusion, 8 (29.6%) of 27
patients described acute severe epigastric and back pain
that lasted for about 5minutes and subsided spontaneously
without analgesic administration. This pain is characteristic
of other liposomal drugs as well.
Although measurement of the response rate was not
a primary goal of the study, 3 (11.1%) of 27 patients
were recorded to have achieved a partial response; of the
remaining 24 patients, 14 (51.9%) achieved stable disease
and clinical beneﬁt in a followup of 2–5 months.
As for Pharmacokinetics, measurement of platinum lev-
elsintheplasma ofpatientsasafunction oftimeshowed that
maximum platinum levelin the plasma (Cmax) was attained
at 6–8 hours after the start of the infusion. Half-life (T1/2)
was 37–50hours depending on the dose, in comparison with
the 6 hours for cisplatin. Excretion of platinum in the urine
reached a maximum duringtheinfusion periodand declined
thereafter. Following a 100mg/m2 infusion, 9.1% of the dose
was excreted in the urine during the 8-hour infusion, and
16.8% and 10% ofthe dose were excreted in the urine during
the following 16 and 24 hours, respectively. During the third
day, an additional 4.8% of the dose was excreted in urine.
Overall,40.7%oftotalplatinumwasexcretedinurineduring
the 3 days after the start of the infusion. Urine excretion
slowed after the third day.
Another open-label, dose-escalation, phase I clinical
study was conduced to identify the MTD and investigate
the pharmacokinetics of Lipoplatin when combined with
gemcitabine, as 2nd-or 3rd- line treatment in patients with
advanced NSCLC [3].
Thirteen patients with stage IIIb (n = 2) or stage IV
(n = 11) NSCLC were enrolled in the study. Lipoplatin
w a sg i v e na sa4 - h o u rI Vi n f u s i o no nd a y s1a n d8o fa2 1 -
day cycle. Gemcitabine 1000mg/m2 was administered as a
30-minute IV infusion prior to the Lipoplatin infusion on
the same days. Doses were 100mg/m2 (n = 3), 110mg/m2
(n = 3), 120mg/m2 (n = 3), and 130mg/m2 (n = 4).
Treatment continued until completion of 3 cycles or disease
progression. Bloodsamples were collectedatpredeﬁned time
intervals after start of the infusion, and analyzed for total
platinum levels.
There were no deaths or SAEs. 75% of the patients at
the 130mg/m2 dose had dose reductionto 120mg/m2 dueto
grade 2-3 myelotoxicity; no hemopoietic factors were given.
Mild elevation in serum creatinine levels was observed in a
single patient in the 130mg/m2 dose; two more patients in
the same dose with prior impaired renal function received
treatment with no aggravation of their renal insuﬃciency.
Mild gastrointestinal toxicity was also seen in the higher
doses. MTD of Lipoplatin in the Lipoplatin plusgemcitabine
combination was deﬁned as the 120mg/m2 dose, DLT being
myelotoxicity.
A disease-control rate of 3 (23%) of 13 was found; the
median overall survival was 29 weeks (range 4–52), and the
median time to progression was 12 weeks.
An open-label, dose-escalation, phase I/II clinical study
was designed to identify the MTD of Lipoplatin when
combined with gemcitabine in patients with advanced
pancreatic cancer refractory to previous gemcitabine-based
chemotherapy [4].Twenty-four patients with stage IIIb (n =
5) or stage IV (n = 19) pancreatic adenocarcinoma were
enrolled in the study. Lipoplatin was given as an 8-hour IV
infusion on days 1 and 14 of a 28-day cycle. Gemcitabine
1000mg/m2 was administered prior to the Lipoplatin infu-
sion on the same days. Doses were 25mg/m2 (n = 4),
50mg/m2 (n = 4), 75mg/m2 (n = 4), 100mg/m2 (n =
4), and 125mg/m2 (n = 4). An additional 4 patients were
enrolled and treated with 100mg/m2, this was deﬁned as
the MTD of this combination and the treatment schedule inChemotherapy Research and Practice 3
Table 1: phase I and II studies with lipoplatin.
Author Chemotherapeutic schema Study phase Diseases Pts N◦ Line OR% SD% mTTP mOS
Stathopoulos
et al. [2]
Lipoplatin 25–125mg/every 2
weeks Phase I Various 27 2nd-3rd 11.1% 51.9%
Froudarakis
et al. [3]
Lipoplatin 100–130mg/m2 days
1 and 8, Gemcitabine
1000mg/m2 d a y s1a n d8q2 1
days
Phase I NSCLC 13 2nd -3rd 7.6% 15.4% 12w 29w
Stathopoulos
et al. [4]
Gemcitabine 1000mg/m2 and
Lipoplatin 25–125mg/m2
administered as an 8 h i.v.
infusion on days 1 and 15, and
cycles were repeated every 4
weeks (28 days)
Phase I-II Pancreatic
cancer 24 2nd 8.3% 58.3% 4m
Ravaioli
et al.[5]
Lipoplatin at 100mg/m2 on days
1, 14 in combination with
gemcitabine 1000mg/m2 on days
1, 8 in a 28-day cycle
Phase I-II Various 38 2nd -3rd 23% 65.3%
Anevlavis
et al. [6]
Lipoplatin 100mg/m2 on day 1
in a 14-day cycle Phase II NSCLC 19 2nd 5.2% 15.9%
Mylonakis
et al. [7]
Lipoplatin 120mg/m2 days 1 and
8 plus gemcitabine 1000mg/m2
d a y s1a n d8e v e r y3w e e k s
Phase II NSCLC 27
2nd
cisplatin
refractory
22.2% 18.5%
Farhat et al.
[8]
Lipoplatin120mg/m2 (days 1, 8
and 15) and gemcitabine
1000mg/m2 (days 1 and 8)
q21-day
Randomized
Phase II NSCLC 47 1st 31.7% 39%
Lipoplatin 120mg/m2 (days 1, 8
and 15) and gemcitabine
1000mg/m2 (days 1 and 8)
q21-days
41 25.6% 30.8%
Koukourakis
et al. [9]
Vinorelbine 30mg/m2 on (days 1
and 8) while Lipoplatin was
administered at the dose of
120mg/m2 on days 1, 8 and 15 q
21d
Phase II MBC 35 53% 36.7%
Jehn et al.
[10]
Lipoplatin 120mg/m2,5 - F Ua t
400mg/m2 (day 1), radiotherapy
3.5 Gy fractions on days 2, 3, and
4i na7 - d a ys c h e d u l e
Phase II Gastric
cancer 6( 4c y c l e s ) 1st-line
LAD 83%
6 (5 cycles) 80%
gemcitabine-pretreated patients. Treatment continued until
completion of 3 cycles or disease progression.
There were no deaths or SAEs. No adverse events were
observed at doses up to 100mg/m2. At the 125mg/m2 dose,
grade 3 and 4 neutropenia was observed in 2 patients, with
no associated symptoms of infection. Temporary abdominal
pain thatlasted for 2–4minutes, and resolved spontaneously,
was observed in 42% of the patients at the beginning of
Lipoplatin infusion. No nephrotoxicity was observed at any
dose. There were no other grade 2, 3, or 4 adverse events.
There was no dose reduction in any of the administered
drugs. MTDofLipoplatin in theLipoplatin plusgemcitabine
combination in gemcitabine-pretreated patients was deﬁned
asthe100mg/m2 dose,DLTbeingmyelotoxicity.Preliminary
objective response rate data showed a PR in 2 (8.3%) and
disease stability in 14 patients (58.3%).
4.Phase II Studies
A number of phase II clinical studies have shown a low
toxicity proﬁle and a therapeutic eﬃcacy of Lipoplatin
against pancreatic cancer and NSCLC when combined with
gemcitabine, paclitaxel, or vinorelbine (Table 1).
InonephaseI-IIstudy,38patientswithadvancedcancers
(19pancreatic,6NSCLC,4mesothelioma, 4urinary bladder,
2 SCCHN, 2 renal, 1 prostate) were treated with Lipoplatin
at 100mg/m2 on days1,14 in combination with gemcitabine
1000mg/m2 on days 1, and 8 in a 28-day cycle as 2nd or
3r dlinec hemotherap y .Thes ideeﬀectsobservedweremainly
those expected from gemcitabine monotherapy, including
myelotoxicity (thrombocytopenia, neutropenia, anaemia).
An average of 4 infusions with Lipoplatin and gemc-
itabine were administered; two patients had 12 infusions.4 Chemotherapy Research and Practice
Table 2: phase III studies with lipoplatin.
Author Chemotherapeutic schema Study
phase Diseases Pts N◦ Line OR% SD% mTTP mOS
Komas et al.
[11]a n d
Stathopoubs
et al. [12]
Lipoplatin 120mg/m2 on days 1, 8, and
15 plus gemcitabine 1g/m2 on days 1 and
8 in a 21-day cycle
Phase III NSCLC 33 1st line 25% 23%
cisplatin 100mg/m2 on day 1 plus
gemcitabine 1g/m2 o nd a y s1a n d8i na
21-day cycle
26 25% 12%
Boulikas et al.
[13]
100mg/m2/d Lipoplatin as a 4h i.v.
i n f u s i o n( d a y s1 ,8 ,1 5 )p l u s
1000mg/m2/d 5-FU (days 1–5
continuous infusion) every 21 days
Phase III SCCHN 25 19% 64%
100mg/ (m2 day) cisplatin with
prehydration and posthydration (day 1)
plus / 1000mg/m2/d / 5-FU (days 1–5
continuous infusion) every 21 days
21 38.8% 50%
Stathopoulos
et al. [14]
Lipoplatin 200mg/m2 plus 135mg/m2
paclitaxel administered on day 1 repeated
every 2 weeks
Phase III 114
(79) 1st line 59.70%
(59.9%) 36.8% 6.5
(10)m 9m
Cisplatin 75mg/m2 135mg/m2 paclitaxel,
administered every 2 weeks
NSCLC (ade-
nocarcinoma
and undiﬀer-
entiated
NSCLC)
115
(73)
47.00%
(42.5%) 43.5% 6 (8)m 10m
There were 3 complete responses in lung lesions; in a patient
with a metastatic lesion from a primary pancreatic cancer,
in a patient with a metastatic lesion from a primary prostate
adenocarcinoma, and in a patient with a primary stage IIIa
NSCLC lesion [4].
Two phase II trials evaluated Lipoplatin in patients
with advanced NSCLC patients who previously underwent
cisplatin-based chemotherapy; in our previous experience,
19 pretreated patients (stage IV) NSCLC were treated with
Lipoplatin 100mg/m2 on day 1 in a 14-day cycle, as 2nd
line treatment. On disease evaluation after 6 cycles, 1 patient
(5.2%) had partial response, and 3 patients (15.9%) had
disease stabilization. The only adverse event was grade 1
gastrointestinal toxicity(nausea/vomiting) [5]. Inthe second
clinical report, patients with NSCLC refractory to Cisplatin
were treated with Lipoplatin 120mg/m2 days 1 and 8
plus gemcitabine 1000mg/m2 d a y s1a n d8e v e r y3w e e k s .
Twenty-seven (77.8%) patients (21 males) were assessable
for response and toxicity according to the WHO criteria
of a median age of 70 years (41–78). Twenty-two (81.5%)
patients were at stage IV at diagnosis; 14 (51.8%) patients
had adenocarcinoma and 13 (48.2%) had squamous-cell
carcinoma in histological type. PR was observed in 6
(22.2%), SD in 5 (18.5%), and progressive disease in 16
(59.2%) patients. With respect to hematological toxicity,
grade 3-4 neutropenia was observed in six (22.2%) patients,
grade3thrombocytopeniainone(3.7%),patientandgrade3
anemiainone(3.7%)patient.Othertoxicitiesincludedgrade
3-4 nausea/emesis in nine (33.3%) patients, grade 3 fever
in nine (33.3%) patients, and grade 3 nephrotoxicity in one
(3.7%) patient. Further toxicities such as rush, constipation,
and peripheral neuropathy were rare and/or mild. Median
overall time to tumor progression was 14 weeks (3–50)
[6].
A phase II randomized, open-label, multicenter, safety
and eﬃcacy clinical trial compared 1st-line treatment with
Lipoplatin plus gemcitabine with that of cisplatin plus
gemcitabine in patients with advanced NSCLC. 88 patients
withinoperablestageI-IIIa(n = 7),stageIIIb(n = 21),orIV
(n = 60) NSCLC were enrolled in the study and assigned to
the Lipoplatin (n = 47) or cisplatin(n = 41) arm. Lipoplatin
120mg/m2 w a sg i v e na sa6 - h o u rI Vi n f u s i o no nd a y s1 ,8 ,
and 15 of a 21-day cycle. Cisplatin 100mg/m2 was given as
a 2-hour IV infusion on day 1 of a 21-day cycle. Patients
in both arms received gemcitabine 1000mg/m2 as a 30-
minuteIVinfusion priortotheLipoplatin/cisplatininfusion,
on days 1 and 8 of the cycle. Treatment was continued
until completionof 6 cycles, unacceptable toxicity, or disease
progression.
There were no deaths or SAEs. Three patients in the
Lipoplatin group had a hypersensitivity reaction during
the ﬁrst Lipoplatin infusion. The commonest toxicities
observed were grade I-II myelotoxicity, with similar rates
between the two arms of treatment. Nevertheless, grade
III-IV myelotoxicity was much more common (1.5 to 2
fold) in the cisplatin arm. Grade II-III nephrotoxicity was
observed in 10.6% of Lipoplatin patients (versus 22%).
Grade I nephrotoxicity was observed in approximately 40–
45% of patients in either group, mostly in single infusions.
Gastrointestinal toxicity was observed to be more frequent
and more severeincisplatinpatients(gradeII-III61% versus
15%). Concerning other adverse events, severe asthenia andChemotherapy Research and Practice 5
anorexia was 5 to 6 fold more common in the cisplatin-
treated patients. Objective response was higher in the
Lipoplatin arm (31.7% versus 25.6%), particularly amongst
patients with adenocarcinoma [7].
Experiencewith Lipoplatinin phase IItrials in metastatic
breast cancer will be presented below [8]. Finally, Lipoplatin
andconcomitantradiotherapy were investigated inaPhase II
study in locally advanced gastric adenocarcinomas. Patients
with locally advanced gastric cancer or gastric cancer inop-
erable for medical reasons, or recurrent carcinomas of a per-
formance status of 0–2 were recruited. Lipoplatin was given
at a dose of 120mg/m2, 5-FU at 400mg/m2 (day 1), while
radiotherapy was giventhrough3.5 Gy fractions on days2, 3,
and 4in a7-dayschedule. Two groupsofsix patientsreceived
4 and 5 consecutive cycles, respectively. Twelve of twenty
planned patients in this study have completed treatment.
N oW H Og r a d e3o r4n e p h r o t o x i c i t y ,a n e m i a ,a s t h e n i a ,o r
neuropathy were noted, except of grade III neutropenia in 1
(8%) of 12 patients. A net improvement of the performance
status was recorded at 2 months after the end of therapy.
The response rates assessed with CT scans, endoscopy, and
biopsies conﬁrmed 33% (2/6) complete remission, 3 (50%)
of 6 PR in patients treated with four cycles, and 4 (80%) of 5
complete remission in patients treated with ﬁve cycles [9].
5.Phase III Trials
The ﬁrst phaseIIIclinicaltrial started in Germany in Decem-
ber 2003 and is still recruiting patients. It is a randomized,
open-label, multicenter safety and eﬃcacy study in patients
with advanced SCCHN [10]. It compares the safety and
eﬃcacy of treatment with Lipoplatin plus 5-Fluorouracil (5-
FU) with that of cisplatin plus 5-FU. Lipoplatin 100mg/m2
is given as a 6-hour IV infusion on days 1, 8, and 15 of
a 21-day cycle. Cisplatin 100mg/m2 is given as a 1-hour
IV infusion on day 1 of the cycle. Patients in both arms
receive continuous infusion of 5-FU 1000 mg/m2/d on days
1–5 of the cycle. Treatment is continued until completion
of 6 cycles, unacceptable toxicity, or disease progression.
The purpose of the study is to show that treatment with
Lipoplatin plus 5-FU gives comparable response and overall
survival to cisplatin plus 5-FU, but is at the same time
better tolerated, and patients have a better quality of life.
Preliminary data show that the toxicity proﬁle is much lower
in the Lipoplatin Arm, with similar clinical beneﬁt.
A second Phase III clinical trial started in Greece in April
2005 and is still recruiting patients. It is a randomized, open-
label, multicenter safety and eﬃcacy study in patients with
advanced NSCLC. The objective of this trial is to compare
the safety and eﬃcacy of 1st line treatment with Lipoplatin
plus gemcitabine with that of cisplatin plus gemcitabine.
Lipoplatin 120mg/m2 is given as a 6-hour IV infusion on
days 1, 8, and 15 of a 21-day cycle. Cisplatin 100mg/m2 is
given as a 2-hour IV infusion on day 1 of a 21-day cycle.
Patients in both arms receive gemcitabine 1000mg/m2 as
a 30-minute IV infusion prior to the Lipoplatin/cisplatin
infusion, on days 1 and 8 of the cycle. Treatment is
continueduntilcompletionof6cycles,unacceptabletoxicity,
or disease progression. The purpose of the study is to
show that Lipoplatin, as 1st line treatment, is not inferior
to cisplatin when combined with gemcitabine (assessed by
overall survival), and is better tolerated. Preliminary results
were presented at the ASCO meeting in 2007 and at the
ESMO meeting in 2009 and show that Lipoplatin may have
a better safety and therapeutic proﬁle than cisplatin, when
combined with gemcitabine, in advanced NSCLC, especially
against adenocarcinomas [11, 13].
Finally, the results of a phase III safety and eﬃcacy
clinical study that compared Lipoplatin plus paclitaxel with
cisplatin plus paclitaxel, as 1st line treatment in NSCLC
have been recently published. Lipoplatin 200mg/m2 or
cisplatin 75mg/m2 was given on day 1 of a 14-day cycle,
combined with paclitaxel 135mg/m2.T r e a t m e n tw a sc o n -
tinued until completion of 9 cycles, unacceptable toxicity,
or disease progression [12]. Patients in Lipoplatin arm
showed statistically signiﬁcant lower nephrotoxicity, grade
3 and 4 leucopenia, grade 2 and 3 neuropathy, nausea,
vomiting, and fatigue. There was no signiﬁcant diﬀerence
in median and overall survival and TTP between the
two arms; median survival was 9 and 10 months in
Lipoplatin and cisplatin arms, respectively, and TTP was
6 . 5a n d6m o n t h s ,r e s p e c t i v e l y .H o w e v e r ,p a t i e n t sw i t h
adenocarcinoma or undiﬀerentiated NSCLC treated with
Lipoplatin had better response rate (59.5% versus 42.5%)
and median survival (10 months versus 8 months) after 18
months; the number of surviving patients was doubled for
the Lipoplatin arm compared with Cisplatin arm (Table 2)
[14].
6.Lipoplatininthe TreatmentofLungCancer
T h e r ea r em a n ye x p e r i e n c e si nt h eu s eo fL i p o p l a t i ni nl u n g
cancer, expecially NSCLC,in Phase 2 and 3 trials. From these
trials, we can underline that the drug is charged by a mild
toxicity, without the eﬀects on kidney and nervous system
characteristic of many other platinum compounds.
Also our group performed a phase II trial in 19
patientswith NSCLCpre-treated with Cisplatin-gemcitabine
(31.5%), Carboplatin-gemcitabine (31.5%), gemcitabine-
docetaxel (31.5%), and gemcitabine (5.5%). The dose of
Lipoplatin used was of 100mg/m2 diluted in 500ml of
5% Dextrose in 8-hour infusion every 2 weeks [5]. Our
results conﬁrm what has been previously reported in the
literature and provide evidence on the safer toxicity proﬁle
of Lipoplatin and its clinical eﬃcacy.
We observed, in these heavily pre-treated patients, one
partial response and three stable disease (21.1%), MTTP of
4 months (range 1–21), median survival time of 7.2 months,
and one-year survival rate of 16.6 %.Very little toxicity was
observed with anemia, mucosities, nausea and vomiting,and
asthenia, all not superior to grade 1-2.
In contrast, few authors have reported more severe
toxicities. Anevlavis et al. [6] treated 27 platinum-refractory
patients were treated with Lipoplatin 120mg/m2 days 1, 8
plus Gemcitabine 1000mg/m2 every 3 weeks with 37% of
PR and SD.6 Chemotherapy Research and Practice
In this experience, the author described some grade 3-4
toxicities, but not neuropathy and only a case of grade 3
nefrotoxicity.
The two randomized trials in NSCLC with Lipoplatin as
ﬁrst line treatment also report interesting results. Mylonakis
et al. treated 88 patients in a phase II randomized trial
comparing LipoplatinorCisplatin (Lipoplatin120mg/mq as
a 6-hour ev infusion 1, 8, and 15 of a 21-day cycle) [7].
Cisplatin100mg/m2 w a sgi v ena satw o- h ourevi n f us i on
ofa21-daycycle.Inbotharms, patientsreceivedgemcitabine
1000mg/m2 on day 1, 8 of the cycle. Also in this experience,
lipoplatin showed less myelotoxicity and grade 2-3 nephro-
toxicity with less severe asthenia and anorexia. Objective
response was higher in the Lipoplatin arm (31.7% versus
25.6%) particurarly among patients with adenocarcinoma.
Finally, theresult of the phase III clinicalstudy compared
Lipoplatin plus paclitaxel versus Cisplatin plus Paclitaxel
as ﬁrst line treatment (Lipoplatin 200mg/m2 or Cisplatin
75mg/m2 on day 1 of a 14-day cycle combined with
Paclitaxel 135mg/m2). Also in this experience, Lipoplatin
arm showed a lower nephrotoxicity, myelotoxicity, and
neurophaty [12, 14]. No diﬀerence was observed in median
overall survival or TTP but patients with adenocarcinoma or
undiﬀerentiated NSCLC treated with lipoplatin had a better
response rate (49.5% versus 42.5%) and median survival (10
against 8 months). After 18 months the number of surviving
patients was doubled for the lipoplatin arm compared with
the Cisplatin arm.
In conclusion,we observed that Lipoplatin is a drug with
the same result of Cisplatin in NSCLC with less toxicities.
The observations of good responses in the histology of ade-
nocarcinoma and undiﬀerenciated NSCLC deserve further
experiences, and a phase III trial in these particular type of
cancers is worthy.
7.LipoplatininBreast Carcinoma
There are very few studies in advanced breast carcinoma.
The experience coming from phase I and II trials is rare
and anecdotal. The paper of Farhat is the only published
experience [8].
The author treated 30 patients with metastatic breast
disease without prior chemotherapy in an advanced setting
with Lipoplatin 120mg/m2 in days 1, 8 and 15 of a 21-day
cycle with vinorelbine 30mg/m2 on days 1, 8.
An objective tumorresponse was observedin 15 % of the
patients; the toxicity was mild to moderate with no grade 3-
4 nephrotoxicity or neuropathy. All the patients were HER 2
negative.
Starting from this experience and knowing the worse
prognosis of “triple-negative” tumors, our attention was
oriented to the possible use of Lipoplatin in this breast
disease subset.
It is well known that this kind of breast tumor is
associated (both in preclinical and clinical studies) with
a high response to traditional chemotherapeutic agents,
expecially alkylating agents or Cisplatin.
A further key feature of triple-negative tumors seems
to be an angiogenetical activity. It has been inferred that
Lipoplatin is endowed with the proprieties of Cisplatin plus
the ability of its nanoparticals to target and kill tumor vas-
cular endothelial cells, suggesting that this drugs combines
chemotherapeutic and antiangiogenetic properties.
For these reasons, our group is going to start a phase
II study in patients with metastatic triple-negative breast
disease. The trial is soon to start.
8.Conclusions
Lipoplatin represents a new very interesting drug, and its use
in advanced lung cancer (NSCLC ) has reached a moderate
validation.
Although in some histology subtypes, like adenocarci-
noma and undiﬀerentiated NSCLC, the drug’s eﬃcacy needs
further investigations.
In breast carcinoma, Lipoplatin represents an interesting
drug expecially in HER 2-negative and in triple-negative
patients, but its eﬃcacy needs further evidence to be
conﬁrmed.
Foritscharacteristics, Lipoplatincouldbeapossibledrug
of interest in other cancers like head and neck, gastric, and
pancreatic cancer.
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